WuXi AppTec (OTCMKTS:WUXAY) Upgraded at Zacks Research

Zacks Research upgraded shares of WuXi AppTec (OTCMKTS:WUXAY) to a hold rating in a research note published on Monday,Zacks.com reports.

Separately, The Goldman Sachs Group upgraded WuXi AppTec to a “buy” rating in a research note on Thursday, February 5th. One analyst has rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy”.

WuXi AppTec Price Performance

WuXi AppTec stock opened at $15.75 on Monday. WuXi AppTec has a fifty-two week low of $5.73 and a fifty-two week high of $16.35. The stock’s 50 day simple moving average is $14.88 and its two-hundred day simple moving average is $14.17.

WuXi AppTec Company Profile

WuXi AppTec is a global contract research, development and manufacturing organization serving the pharmaceutical, biotechnology and medical device industries. Headquartered in Shanghai and founded in 2000, the company provides end-to-end solutions that span drug discovery, development and manufacturing. Its offerings enable customers to accelerate the research and development process for small molecules, biologics, cell and gene therapies, as well as medical devices.

Key services include chemistry and biology discovery support, preclinical safety assessment, analytical and formulation development, clinical manufacturing, large-scale biomanufacturing, and quality testing.